#News 🎉 November 21, 2023 -- Connect Biopharma announced that it has entered into an exclusive license and collaboration agreement with Simcere to develop and commercialize Connect Biopharma’s rademikibart in Greater China. rademikibart (CBP-201) is an antibody designed to target IL-4Rα in development for the treatment of atopic dermatitis (AD) and asthma. Dupilumab, the IL-4Rα monoclonal antibody co-developed by Sanofi and Regeneration, has been launched in 2017. Dupilumab generated sales of €4.9bn in H1 2023 and it expected to across the €10bn market. 🔹 DDXCELL provides one-stop cell development service and related cell products to meet needs of drug research, including IL-4 and IL-13 stable cell lines. 👉 Click the link to know products: https://lnkd.in/g2_7s-QV #celllinedevelopment #cancertreatment #drugdiscovery #antibody #ADC #cytokines #asthma #atopicdermatitis
